AURA vs. URGN, UROV, PSNL, PRQR, IVA, EVO, NAMS, AVDL, KURA, and KNSA
Should you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include UroGen Pharma (URGN), Urovant Sciences (UROV), Personalis (PSNL), ProQR Therapeutics (PRQR), Inventiva (IVA), Evotec (EVO), NewAmsterdam Pharma (NAMS), Avadel Pharmaceuticals (AVDL), Kura Oncology (KURA), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "medical" sector.
Aura Biosciences (NASDAQ:AURA) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings.
Aura Biosciences has higher earnings, but lower revenue than UroGen Pharma. Aura Biosciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
Aura Biosciences presently has a consensus price target of $21.00, suggesting a potential upside of 102.70%. UroGen Pharma has a consensus price target of $51.17, suggesting a potential upside of 212.95%. Given UroGen Pharma's higher possible upside, analysts plainly believe UroGen Pharma is more favorable than Aura Biosciences.
Aura Biosciences has a net margin of 0.00% compared to UroGen Pharma's net margin of -123.74%. UroGen Pharma's return on equity of 0.00% beat Aura Biosciences' return on equity.
96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are held by institutional investors. 5.4% of Aura Biosciences shares are held by insiders. Comparatively, 5.1% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Aura Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.
In the previous week, Aura Biosciences had 5 more articles in the media than UroGen Pharma. MarketBeat recorded 6 mentions for Aura Biosciences and 1 mentions for UroGen Pharma. UroGen Pharma's average media sentiment score of 1.87 beat Aura Biosciences' score of 0.41 indicating that UroGen Pharma is being referred to more favorably in the news media.
UroGen Pharma received 345 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 73.51% of users gave UroGen Pharma an outperform vote while only 48.15% of users gave Aura Biosciences an outperform vote.
Summary
Aura Biosciences and UroGen Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Aura Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aura Biosciences Competitors List
Related Companies and Tools
